周五盘中，生物技术公司AbCellera Biologics（股票代码：ABCL）股价出现暴跌，跌幅高达20.31%，引发市场广泛关注。这一大幅下跌主要源于知名投资银行Leerink Partners对该公司评级的下调。
据悉，Leerink Partners将AbCellera Biologics的投资评级从"跑赢大盘"下调至"市场表现"，同时将目标价从5美元下调至4美元。这一评级调整反映了分析师对公司未来表现预期的显著降低，直接导致投资者信心受挫，引发了股价的大幅下跌。
AbCellera Biologics是一家专注于抗体发现和开发的生物技术公司。此次评级下调可能暗示投资者对公司的业务前景和市场竞争力产生了担忧。面对如此大幅度的股价下跌，投资者需密切关注公司未来的业务发展和市场表现，以评估其长期投资价值。市场将继续关注AbCellera Biologics的后续表现，以及公司如何应对这一挑战。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.